Palbociclib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2524 publications
Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744].
Journal: Breast (Edinburgh, Scotland)
Published: April 05, 2026
Assessing cancer cell heterogeneity in patient-derived tumoroids.
Journal: Methods in cell biology
Published: March 30, 2026
Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.
Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026
Inflation Reduction Act impact on the hematology/oncology treatment landscape.
Journal: The American journal of managed care
Published: March 26, 2026
Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America.
Journal: JCO global oncology
Published: March 19, 2026
Triple-Synergistic Therapy with Cobalt-Pheophytin Coordination Micelles for Overcoming Drug Resistance in Pancreatic Cancers.
Journal: ACS applied bio materials
Published: March 17, 2026
Formulation Design, Optimization, and In Vitro Evaluation of Palbociclib-Loaded Polymeric Nanoparticles.
Journal: Assay and drug development technologies
Published: March 10, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 09, 2026
HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 02, 2026
Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.
Journal: Journal of pharmaceutical policy and practice
Published: February 23, 2026
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
Journal: Breast cancer research and treatment
Published: February 18, 2026
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Last Updated: 04/28/2026